Skip to main content

Advertisement

SpringerLink
Log in

Letter to the editor regarding ‘Stereotactic radiosurgery for bone metastases in oligometastatic prostate cancer patients: DESTROY‑2 clinical trial subanalysis’

  • Correspondence
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

A Correspondence to this article was published on 19 March 2022

The Original Article was published on 04 January 2022

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Deodato F, Pezzulla D, Cilla S, et al. Stereotactic radiosurgery for bone metastases in oligometastatic prostate cancer patients: DESTROY-2 clinical trial subanalysis. Clin Transl Oncol. 2022. https://doi.org/10.1007/s12094-021-02764-w.

    Article  PubMed  Google Scholar 

  2. Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208–16.

    Article  CAS  Google Scholar 

  3. Perera M, Papa N, Roberts M, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. 2020;77:403–17.

    Article  Google Scholar 

  4. Jereczek-Fossa BA, Beltramo G, Fariselli L, et al. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82:889–97.

    Article  Google Scholar 

  5. Bouman-Wammes EW, van Dodewaard-De Jong JM, Dahele M, et al. Benefits of using stereotactic body radiotherapy in patients with metachronous oligometastases of hormone-sensitive prostate cancer detected by [18F]fluoromethylcholine PET/CT. Clin Genitourin Cancer. 2017;15:e773–82.

    Article  Google Scholar 

  6. Onal C, Ozyigit G, Oymak E, et al. Stereotactic radiotherapy to oligoprogressive lesions detected with (68)Ga-PSMA-PET/CT in castration-resistant prostate cancer patients. Eur J Nucl Med Mol Imaging. 2021;48:3683–92.

    Article  CAS  Google Scholar 

  7. Onal C, Ozyigit G, Akgun Z, et al. Oligometastatic bone disease in castration-sensitive prostate cancer patients treated with stereotactic body radiotherapy using 68Ga-PSMA PET/CT: TROD 09–004 study. Clin Nucl Med. 2021;46:465–70.

    Article  Google Scholar 

  8. Phillips R, Shi WY, Deek M, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6:650–9.

    Article  Google Scholar 

  9. Kneebone A, Hruby G, Ainsworth H, et al. Stereotactic body radiotherapy for oligometastatic prostate cancer detected via prostate-specific membrane antigen positron emission tomography. Eur Urol Oncol. 2018;1:531–7.

    Article  Google Scholar 

Download references

Funding

No funding was received for this work.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Adana Dr. Turgut Noyan Research and Treatment Center, Baskent University Faculty of Medicine, 01120, Adana, Turkey

    Cem Onal

  2. Department of Radiation Oncology, Baskent University Faculty of Medicine, Ankara, Turkey

    Cem Onal

  3. Division of Radiation Oncology, Iskenderun Gelisim Hospital, Hatay, Turkey

    Ezgi Oymak

Authors
  1. Cem Onal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ezgi Oymak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cem Onal.

Ethics declarations

Conflict of interest

The other authors declare that there are no conflicts of interest in this work.

Ethical approval (research involving human participants and/or animals)

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

For this type of study, no informed consent is required.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Onal, C., Oymak, E. Letter to the editor regarding ‘Stereotactic radiosurgery for bone metastases in oligometastatic prostate cancer patients: DESTROY‑2 clinical trial subanalysis’. Clin Transl Oncol 24, 1215–1216 (2022). https://doi.org/10.1007/s12094-022-02812-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-022-02812-z

Search

Navigation